Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $85,995.21 in Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee sold 1,447 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $85,995.21. Following the transaction, the executive vice president now owns 4,038 shares of the company’s stock, valued at approximately $239,978.34. The trade was a 26.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jennifer Kayden Lee also recently made the following trade(s):

• On Monday, November 11th, Jennifer Kayden Lee sold 66,861 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $66.33, for a total value of $4,434,890.13.

Rhythm Pharmaceuticals Trading Down 1.7 %

NASDAQ:RYTM opened at $60.01 on Friday. The company has a fifty day moving average of $57.37 and a 200 day moving average of $53.19. Rhythm Pharmaceuticals, Inc. has a 52 week low of $35.17 and a 52 week high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.07. The firm had revenue of $33.20 million during the quarter, compared to the consensus estimate of $32.52 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company’s quarterly revenue was up 47.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.76) earnings per share. On average, sell-side analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.33 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on RYTM. Bank of America upped their price objective on shares of Rhythm Pharmaceuticals from $48.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, October 14th. The Goldman Sachs Group lifted their price objective on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. TD Cowen raised their price target on Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. HC Wainwright reaffirmed a “buy” rating and set a $69.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. Finally, Guggenheim began coverage on Rhythm Pharmaceuticals in a report on Monday, October 21st. They set a “buy” rating and a $70.00 price objective on the stock. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $68.09.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Large investors have recently made changes to their positions in the business. Freestone Capital Holdings LLC bought a new position in shares of Rhythm Pharmaceuticals during the fourth quarter valued at approximately $207,000. Raymond James Financial Inc. bought a new position in Rhythm Pharmaceuticals in the 4th quarter worth $218,000. Charles Schwab Investment Management Inc. lifted its position in shares of Rhythm Pharmaceuticals by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 440,250 shares of the company’s stock worth $24,645,000 after purchasing an additional 6,384 shares during the period. SBI Securities Co. Ltd. bought a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter valued at about $37,000. Finally, SRS Capital Advisors Inc. raised its stake in Rhythm Pharmaceuticals by 740.7% in the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock worth $25,000 after buying an additional 400 shares in the last quarter.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.